Best in Biotech 1 Dec 2025 Stem cell therapy’s avant-garde: Eight companies leading the way …an emerging player in regenerative neurology, building on a decade of expertise in producing high-purity neurons and glia from human iPSCs. Originally focused on supplying subtype-specific human central nervous system (CNS) cells for research… December 1, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2018 Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets …central nervous system (CNS), as well as metabolic diseases. Led by the former CSO of Ablynx, a biotech that was acquired by Sanofi for €3.9Bn earlier this year, Evox… September 3, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2022 PrecisionLife to work on R&D with Ono Pharmaceutical …and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyzes multi-modal datasets including genomic, clinical, and epidemiological data to stratify patients and understand subgroup-relevant… December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2023 Schizophrenia injection gets FDA approval …evaluating UZEDY in patients with schizophrenia: TV46000-CNS-30072 (the RISE study), and TV46000-CNS-30078 (the SHINE study). “The approval of the first product formulated with our technology is a pivotal moment for… May 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 30 Jul 2025 Targeting orexin: the future of narcolepsy treatments …is made of sodium oxybate, a central nervous system (CNS) depressant. A CNS depressant, colloquially known as a ‘downer,’ is meant to slow down brain activity. London-based Hikma Pharmaceuticals has… July 30, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Apr 2025 21 UK biotech companies you should know about …are currently for undisclosed central nervous system (CNS) indications. Back in 2020, Evox Therapeutics signed a major deal with Eli Lilly, worth up to $1.1 billion. The research collaboration and… April 24, 2025 - 27 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 29 Oct 2025 Parkinson’s disease: biotech’s pursuit for more therapies …the clinic was forged between Belgian central nervous system (CNS) disease therapeutics company Clouds of Care and Swiss research company Indivi. Set on advancing precision medicine, the two will combine neuro-electrophysiology with digital health technology… October 29, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2023 Five biotech companies taking Los Angeles by storm …with $140 million, Capsida began with a focus on central nervous system (CNS) disorders, and has since expanded into serious eye diseases through its partnership with AbbVie. The Los Angeles… September 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval …an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World Parkinson’s Day on April… May 12, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: IRLAB CEO Richard Godfrey IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in phase IIb and are… December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Mar 2023 5 women leading the way in biotech …for the treatment of central nervous system (CNS) disorders including therapies for schizophrenia and Parkinson’s disease. She believes that there is plenty of scope in polypharmacology, which is the use… March 8, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia? …Novartis announced it’s looking to get rid of its CNS portfolio, which is also based on small molecules. TxCell has made a deal with Inserm Transfert for its CD8+ Tregs…. December 9, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email